Medical Pharmacology: Chapter 18: Antiparkinson's Disease Drugs -- Module 6: Anticholinergics, Amantadine ER, and Adjunct Pharmacology

Chapter 18: Antiparkinson's Disease Drugs — Module 6: Anticholinergics, Amantadine ER, and Adjunct Pharmacology
Tier: T1

1. A 45-year-old woman with schizophrenia has been started on haloperidol. Three weeks later she develops resting tremor, bradykinesia, and masked facies. Her psychiatrist adds benztropine. Which of the following best explains why anticholinergic therapy is mechanistically appropriate for this patient's motor syndrome, and how this differs from the rationale for anticholinergic use in idiopathic Parkinson's disease (PD)?

A) In both drug-induced parkinsonism (DIP) and idiopathic PD, anticholinergics work by stimulating residual dopaminergic neurons in the substantia nigra; in DIP the effect is larger because more neurons remain intact.
B) Anticholinergics are not appropriate for DIP because haloperidol's D2 blockade is irreversible; benztropine cannot overcome pharmacological D2 receptor occupancy and will only worsen the anticholinergic adverse effect burden.
C) In DIP, haloperidol's D2 receptor blockade prevents dopamine from suppressing striatal cholinergic interneurons, producing relative cholinergic excess by a pharmacological mechanism rather than nigrostriatal degeneration; benztropine corrects this imbalance by muscarinic blockade, using the same pharmacological principle as in idiopathic PD but without the underlying neurodegeneration.
D) Anticholinergics are appropriate in DIP because haloperidol directly stimulates muscarinic M1 receptors in the striatum as an off-target effect; benztropine competitively antagonizes this direct receptor activation.
E) In DIP, anticholinergics work by accelerating haloperidol metabolism through CYP2D6 induction, reducing D2 receptor occupancy and allowing dopamine to resume normal striatal function.

ANSWER: C

Rationale:

The pathophysiological basis of anticholinergic efficacy is the same in drug-induced parkinsonism (DIP) and idiopathic PD: both conditions produce relative cholinergic excess in the striatum by disrupting the normal dopaminergic suppression of tonically active cholinergic interneurons. In idiopathic PD, this disruption results from nigrostriatal dopaminergic neuron degeneration, reducing the amount of dopamine available to suppress cholinergic interneurons. In DIP caused by haloperidol, the nigrostriatal neurons are structurally intact but functionally blocked — haloperidol's high-affinity D2 receptor antagonism prevents dopamine from binding to its receptors on cholinergic interneurons, achieving the same net result of cholinergic disinhibition and excess. Benztropine corrects this imbalance by muscarinic receptor blockade, reducing the functional consequences of cholinergic overactivity. The key clinical distinction is that DIP is reversible with dose reduction or discontinuation of the offending agent; idiopathic PD is not. Option C correctly identifies the shared pharmacological principle and the mechanistic difference between the two conditions.

Option A: Option A is incorrect; anticholinergics do not stimulate dopaminergic neurons — they block muscarinic receptors, and their mechanism is unrelated to residual nigrostriatal neuron activity.
Option B: Option B is incorrect; haloperidol's D2 blockade is competitive and reversible, not irreversible, and benztropine's muscarinic blockade is mechanistically independent of D2 receptor occupancy — it targets the downstream consequence of dopaminergic dysfunction, not the D2 receptor itself.
Option D: Option D is incorrect; haloperidol does not directly stimulate muscarinic M1 receptors — its relevant off-target effects include histamine H1 and alpha-adrenergic blockade, but M1 agonism is not among them.
Option E: Option E is incorrect; benztropine does not induce CYP2D6 or accelerate haloperidol metabolism — its mechanism is entirely pharmacodynamic, not pharmacokinetic.

2. A 78-year-old man with Parkinson's disease (PD) dementia has been taking trihexyphenidyl 2 mg three times daily for six years, prescribed originally for tremor control. Over the past four months his caregiver reports worsening confusion, agitation, and visual hallucinations. His neurologist decides to discontinue trihexyphenidyl. Which of the following correctly describes the appropriate discontinuation strategy and the rationale for it?

A) Trihexyphenidyl should be tapered gradually over weeks to months — reducing the dose by approximately 25 to 50 percent every two to four weeks — because abrupt discontinuation after prolonged use can precipitate a withdrawal syndrome including nausea, sweating, and anxiety, as well as rebound worsening of tremor; if tremor worsens significantly during taper, bridging with propranolol or clonazepam should be considered before completing discontinuation.
B) Trihexyphenidyl should be discontinued abruptly because the cognitive and behavioral adverse effects it is causing represent a medical emergency that outweighs any risk of withdrawal; the withdrawal syndrome from anticholinergics is mild and self-limited and does not require a taper in patients who are cognitively impaired.
C) Trihexyphenidyl should be cross-tapered to benztropine at an equivalent dose over two weeks before stopping entirely, because benztropine's longer duration of action provides a pharmacokinetic self-taper that prevents withdrawal symptoms and tremor rebound.
D) Trihexyphenidyl dose should be halved immediately and then maintained at the lower dose indefinitely, since complete discontinuation of anticholinergics in patients with PD dementia universally precipitates intractable tremor that cannot be managed by other agents.
E) Trihexyphenidyl should be discontinued abruptly and the patient should be started immediately on a dopamine agonist at full dose to suppress both tremor rebound and the withdrawal syndrome through direct D2 receptor stimulation.

ANSWER: A

Rationale:

Gradual tapering is the correct approach to anticholinergic discontinuation after prolonged use, regardless of how urgent the clinical indication for stopping may be. Abrupt discontinuation of long-term anticholinergic therapy carries two risks: a withdrawal syndrome characterized by nausea, sweating, and anxiety caused by cholinergic rebound, and significant worsening of parkinsonian tremor as the muscarinic blockade that was partially controlling tremor is suddenly removed. The appropriate strategy is to reduce the dose by approximately 25 to 50 percent every two to four weeks, monitoring for tremor worsening throughout. If tremor worsens to a clinically unacceptable degree during the taper, bridging with a non-anticholinergic tremor-suppressing agent such as propranolol or clonazepam can provide temporary coverage while the taper continues to completion. The urgency of the cognitive and behavioral adverse effects makes rapid tapering appropriate — a faster taper within this range — but does not justify abrupt discontinuation. Option A correctly describes this strategy and its rationale.

Option B: Option B is incorrect; while the cognitive adverse effects are serious and warrant prioritizing discontinuation, the withdrawal risks from abrupt cessation are real and not trivially mild, particularly in an elderly patient with PD — the taper can be expedited but not eliminated.
Option C: Option C is incorrect; switching to benztropine does not constitute a taper and does not leverage a pharmacokinetic self-taper — benztropine is also an anticholinergic that requires its own taper when discontinued, and the underlying problem of anticholinergic burden is not resolved by agent substitution.
Option D: Option D is incorrect; indefinite maintenance at a reduced dose is not appropriate when the patient has cognitive impairment that contraindicates any degree of anticholinergic use — the goal is complete discontinuation, not dose reduction to a maintenance level.
Option E: Option E is incorrect; abrupt discontinuation is hazardous regardless of what is added simultaneously, and initiating a dopamine agonist at full dose in a patient with PD dementia and active hallucinations carries a high risk of worsening psychosis — dopamine agonists are among the agents most likely to worsen hallucinations in this population.

3. A 67-year-old woman with advanced Parkinson's disease (PD) on levodopa/carbidopa 25/100 mg five times daily develops functionally significant choreiform dyskinesia during peak-dose periods. Her neurologist considers two options: reducing the levodopa dose or adding amantadine extended-release (ER) 137 mg at bedtime. Which of the following best explains why amantadine ER is preferred over levodopa dose reduction as the primary strategy for dyskinesia management in this patient?

A) Amantadine ER is preferred because it directly blocks dopamine D1 receptors on direct pathway neurons, reducing the pathological direct pathway overactivation that generates dyskinesia without affecting the D2-mediated motor benefit of levodopa.
B) Amantadine ER is preferred because it inhibits catechol-O-methyltransferase (COMT), reducing levodopa's peak plasma concentration and smoothing the dopamine surges that drive peak-dose dyskinesia, while simultaneously extending levodopa's duration of action to prevent wearing-off.
C) Levodopa dose reduction is preferred over amantadine ER because it directly addresses the pharmacokinetic cause of peak-dose dyskinesia, whereas amantadine ER only treats the symptom without modifying the underlying dopamine fluctuation pattern.
D) Amantadine ER is preferred because adenosine A2A receptor blockade on striatopallidal neurons reduces indirect pathway overactivity, correcting the pathway imbalance that generates dyskinesia without altering dopaminergic tone.
E) Amantadine ER is preferred because its uncompetitive N-methyl-D-aspartate (NMDA) receptor antagonism reduces dyskinesia through a glutamatergic mechanism that is independent of dopaminergic signaling, allowing dyskinesia control without the loss of on-time and motor function that levodopa dose reduction would impose.

ANSWER: E

Rationale:

The central clinical advantage of amantadine ER over levodopa dose reduction for dyskinesia management is that its mechanism — uncompetitive NMDA receptor antagonism — operates through the glutamatergic pathway independently of dopaminergic signaling. Levodopa-induced dyskinesia arises from pathological corticostriatal plasticity driven in part by abnormal NMDA receptor-mediated glutamatergic signaling in the basal ganglia; amantadine ER attenuates this glutamatergic drive, reducing dyskinesia without altering levodopa's dopaminergic motor benefit. In contrast, reducing the levodopa dose directly curtails dopaminergic stimulation, which reduces dyskinesia at the cost of increased off-time and worsened motor function during the remaining on-periods — trading one problem for another. The EASE LID trials demonstrated that amantadine ER reduced Unified Dyskinesia Rating Scale (UDysRS) scores by approximately 41% from baseline versus approximately 14% with placebo — a placebo-subtracted difference of roughly 27% — while simultaneously reducing daily off-time by approximately 1 hour, confirming that dyskinesia control can be achieved without sacrificing motor on-time. Option E correctly identifies this mechanistic independence as the basis for preferring amantadine ER.

Option A: Option A is incorrect; amantadine does not have clinically significant D1 receptor antagonist activity, and D1 blockade would worsen parkinsonism by opposing the direct pathway that mediates voluntary movement.
Option B: Option B is incorrect; amantadine ER does not inhibit COMT — COMT inhibition is the mechanism of entacapone and tolcapone, which reduce wearing-off; COMT inhibitors can actually worsen dyskinesia by increasing peak levodopa exposure.
Option C: Option C is incorrect and reverses the clinical priority; levodopa dose reduction sacrifices motor function to reduce dyskinesia and is not preferred when an agent can address dyskinesia through an independent mechanism without this trade-off.
Option D: Option D is incorrect; adenosine A2A receptor blockade is the mechanism of istradefylline, which targets off-time reduction rather than dyskinesia — conflating istradefylline's mechanism with amantadine ER's is a high-yield distractor at the T1 level.

4. A 71-year-old man with Parkinson's disease (PD) and stage 4 chronic kidney disease (CKD) has levodopa-induced dyskinesia that is limiting his daily function. His creatinine clearance (CrCl) is 22 mL/min. His neurologist considers amantadine extended-release (ER) 137 mg at bedtime. Which of the following represents the correct prescribing decision for this patient?

A) Amantadine ER may be initiated at the standard dose of 137 mg at bedtime because hepatic metabolism is the primary elimination pathway and renal function does not meaningfully affect steady-state drug exposure.
B) Amantadine ER should not be prescribed in this patient because a creatinine clearance below 30 mL/min is an absolute contraindication to its use, and no dose adjustment exists for any patient below this threshold.
C) Amantadine ER should be prescribed at 68.5 mg once daily at bedtime — the recommended initial and maximum dose for severe renal impairment (creatinine clearance 15 to 29 mL/min) — because amantadine is renally eliminated and accumulates in renal impairment; the drug is contraindicated only in end-stage renal disease (creatinine clearance below 15 mL/min).
D) Amantadine ER should be initiated at 137 mg at bedtime and then reduced only if the patient develops hallucinations or confusion, since reactive dose reduction is preferred over empiric renal dose adjustment.
E) Amantadine ER should be prescribed at 68.5 mg every other day, since the every-other-day schedule is the approved regimen for creatinine clearance between 15 and 29 mL/min and approximates normal-renal-function exposure.

ANSWER: C

Rationale:

Amantadine is predominantly renally eliminated, and the approved prescribing information for Gocovri (amantadine ER) specifies renal dose adjustments by creatinine clearance band: for moderate impairment (creatinine clearance 30 to 59 mL/min), the initial dose is 68.5 mg once daily at bedtime with a maximum of 137 mg once daily; for severe impairment (creatinine clearance 15 to 29 mL/min), 68.5 mg once daily at bedtime is both the recommended initial and maximum dose; and the drug is contraindicated only in end-stage renal disease (creatinine clearance below 15 mL/min). This patient's CrCl of 22 mL/min falls within the severe impairment band, where the drug is not contraindicated but must be dosed at 68.5 mg once daily, with monitoring for CNS adverse effects such as hallucinations, confusion, and myoclonus that reflect amantadine accumulation. Option C correctly identifies the 68.5 mg dose for this CrCl and correctly locates the contraindication threshold at end-stage renal disease.

Option A: Option A is incorrect; amantadine is not primarily hepatically metabolized — it is renally eliminated, and renal function is the primary determinant of drug clearance and accumulation risk, mandating dose reduction in severe impairment.
Option B: Option B is incorrect; a creatinine clearance below 30 mL/min is not a contraindication — the contraindication applies only at end-stage renal disease (creatinine clearance below 15 mL/min), and patients in the 15 to 29 mL/min severe band are dosed at 68.5 mg once daily.
Option D: Option D is incorrect; the approved approach in renal impairment is proactive dose reduction by creatinine clearance band, not initiation at the full 137 mg dose with reactive reduction after toxicity emerges.
Option E: Option E is incorrect; every-other-day dosing at 68.5 mg is not an approved or validated regimen — the prescribing information specifies 68.5 mg once daily for creatinine clearance 15 to 29 mL/min, not an alternative dosing interval.

5. A 69-year-old man with Parkinson's disease (PD) and epilepsy is being evaluated for istradefylline to reduce off-time. He has moderate hepatic impairment (Child-Pugh class B) and is taking carbamazepine for seizure control. Which of the following best characterizes the combined pharmacokinetic problem posed by this patient's clinical situation and the appropriate prescribing decision?

A) Moderate hepatic impairment reduces CYP3A4 activity, increasing istradefylline plasma concentrations; carbamazepine inhibits CYP3A4, compounding this effect; the combination requires dose reduction to 10 mg once daily to avoid toxicity.
B) Carbamazepine is a CYP3A4 inhibitor that raises istradefylline levels, which is beneficial in a patient with moderate hepatic impairment because it compensates for reduced hepatic clearance; no dose adjustment is needed.
C) Moderate hepatic impairment has no effect on istradefylline pharmacokinetics because CYP3A4 is expressed primarily in the intestinal wall rather than the liver; carbamazepine's interaction with intestinal CYP3A4 is the clinically relevant factor, requiring a dose increase to 40 mg.
D) Carbamazepine is a potent CYP3A4 inducer that substantially reduces istradefylline plasma concentrations; in a patient with moderate hepatic impairment already capped at a maximum dose of 20 mg once daily, co-administration of a strong CYP3A4 inducer that further reduces already-limited drug exposure creates an untenable pharmacokinetic situation, and istradefylline should not be prescribed in this patient.
E) The combination is acceptable at the standard 20 mg once daily dose because moderate hepatic impairment and CYP3A4 induction by carbamazepine have opposing effects on istradefylline exposure that largely cancel each other out, producing near-normal plasma concentrations.

ANSWER: D

Rationale:

This question stacks two independent pharmacokinetic problems that, together, make istradefylline impractical in this patient. Istradefylline is metabolized primarily by CYP1A1 and CYP3A4. In moderate hepatic impairment (Child-Pugh class B), reduced metabolic capacity increases istradefylline exposure, which is why the prescribing information caps the maximum dose at 20 mg once daily in this population — uptitration to 40 mg is not permitted. Carbamazepine is a potent CYP3A4 inducer: it dramatically upregulates CYP3A4 activity and accelerates istradefylline catabolism, substantially reducing plasma concentrations — the prescribing information states that strong CYP3A4 inducers significantly reduce istradefylline levels and that the combination should be avoided. In a patient who is already limited to the 20 mg dose by hepatic impairment, adding a strong CYP3A4 inducer that reduces exposure at that dose leaves no room to compensate — uptitration to 40 mg is prohibited by the hepatic impairment cap. The result is a patient who cannot receive the dose needed to overcome the induction effect and for whom istradefylline is therefore not a viable option. Option D correctly identifies this compounded pharmacokinetic problem and the appropriate conclusion.

Option A: Option A is incorrect in two ways: carbamazepine is a CYP3A4 inducer, not an inhibitor, and a 10 mg dose of istradefylline does not exist in the approved regimen.
Option B: Option B is incorrect; carbamazepine is an inducer, not an inhibitor — it lowers, not raises, istradefylline levels, which is harmful rather than beneficial in this context.
Option C: Option C is incorrect; while intestinal CYP3A4 does contribute to first-pass metabolism of some drugs, hepatic CYP3A4 is the primary site of istradefylline clearance and moderate hepatic impairment does meaningfully affect its pharmacokinetics.
Option E: Option E is incorrect; the effects do not cancel each other — hepatic impairment reduces clearance while carbamazepine induction increases it, but the net direction and magnitude are unpredictable and the prescribing information does not endorse this combination on any basis.

6. A 74-year-old man with tremor-dominant Parkinson's disease (PD) has resting tremor that remains incompletely controlled on optimized levodopa therapy. His past medical history is significant for benign prostatic hyperplasia (BPH) managed with tamsulosin, narrow-angle glaucoma treated with topical pilocarpine, and mild cognitive impairment (MCI). His neurologist considers adding trihexyphenidyl for tremor control. Which of the following is the most appropriate assessment?

A) Trihexyphenidyl is contraindicated in this patient on multiple independent grounds: BPH with pre-existing urinary obstruction creates high risk for acute urinary retention from detrusor muscarinic blockade; narrow-angle glaucoma creates risk for acute angle-closure crisis from anticholinergic-induced mydriasis; age over 70 and the presence of MCI are both independent contraindications given the high risk of worsening cognitive function through central muscarinic blockade in a patient with reduced cholinergic reserve.
B) Trihexyphenidyl is appropriate because tamsulosin's alpha-1 blockade will protect against urinary retention by keeping the bladder outlet open, and topical pilocarpine's miotic effect will counteract anticholinergic mydriasis, effectively neutralizing both peripheral contraindications; MCI is the only remaining concern.
C) Trihexyphenidyl is appropriate at a low starting dose of 0.5 mg daily because the peripheral contraindications of BPH and glaucoma apply only to systemic anticholinergic doses above 4 mg daily, and titration can be halted if intraocular pressure or urinary symptoms worsen.
D) Trihexyphenidyl is contraindicated solely because of the narrow-angle glaucoma, but the BPH and MCI do not independently preclude its use — tamsulosin provides sufficient urological protection and MCI alone is not a contraindication unless the patient scores below a threshold on formal cognitive testing.
E) Trihexyphenidyl should be trialed for four weeks at 1 mg three times daily with weekly intraocular pressure monitoring and post-void residual measurement, discontinuing only if objective worsening is documented rather than applying contraindications as absolute rules.

ANSWER: A

Rationale:

This patient has three independent contraindications to anticholinergic therapy, any one of which would be sufficient to rule out its use. First, BPH with pre-existing urinary outflow obstruction: muscarinic M3 receptor blockade on the detrusor muscle reduces bladder contractility, and in a patient already struggling against urethral resistance from prostatic hypertrophy, this can precipitate acute urinary retention — a urological emergency. Second, narrow-angle glaucoma: anticholinergic-induced mydriasis causes the peripheral iris to fold against the trabecular meshwork in an eye with a shallow anterior chamber angle, obstructing aqueous humor outflow and precipitating acute angle-closure crisis with rapid, potentially irreversible intraocular pressure elevation. Third, age over 70 combined with MCI: PD itself depletes cortical and hippocampal cholinergic signaling, and adding central muscarinic blockade in a patient with already-reduced cholinergic reserve and pre-existing mild cognitive impairment carries a high probability of precipitating acute confusion, worsening cognitive function, or hallucinations. When all three contraindications are present simultaneously, anticholinergic therapy is definitively ruled out. Option A correctly identifies all three contraindications and their mechanistic bases.

Option B: Option B is incorrect; tamsulosin's alpha-1 blockade relaxes urethral smooth muscle but does not restore detrusor contractility — it addresses one side of the voiding equation but cannot compensate for the loss of detrusor function caused by muscarinic blockade; similarly, topical pilocarpine maintains miosis at rest but cannot reliably counteract systemic anticholinergic mydriasis, particularly during peak drug absorption.
Option C: Option C is incorrect; there is no dose threshold below which BPH and narrow-angle glaucoma become safe for anticholinergic use — both represent pharmacodynamic risks that are present at any dose sufficient to produce systemic muscarinic blockade.
Option D: Option D is incorrect; MCI is an independent contraindication to anticholinergics in PD, not a relative concern requiring formal cognitive scoring — and BPH is not adequately mitigated by tamsulosin for purposes of anticholinergic prescribing.
Option E: Option E is incorrect; monitoring for objective worsening does not replace contraindication assessment — acute angle-closure crisis and acute urinary retention are medical emergencies that can cause irreversible harm before monitoring detects them, and the appropriate action is to not initiate the drug.

7. A 70-year-old woman with Parkinson's disease (PD) has been taking amantadine extended-release (ER) 137 mg at bedtime for two years for levodopa-induced dyskinesia. She is admitted to hospital for elective hip replacement surgery. On the morning of surgery her nursing orders include "hold all non-essential medications." The admitting team stops amantadine ER abruptly. On postoperative day two she develops markedly worsened rigidity, bradykinesia, and tremor, and her physical therapist notes she is now unable to participate in rehabilitation. Which of the following best explains this deterioration and the correct management principle?

A) Abrupt discontinuation of amantadine ER is safe because its mechanism of action — NMDA receptor antagonism — does not produce physical dependence, and the postoperative deterioration represents natural disease progression unmasked by surgical stress rather than a drug withdrawal effect.
B) The postoperative motor deterioration reflects dopaminergic rebound from the sudden loss of amantadine's dopamine-releasing effect; it should be managed by increasing the levodopa dose by 50 percent until amantadine ER can be restarted.
C) Amantadine ER should not be stopped abruptly after prolonged use because discontinuation can precipitate significant rebound worsening of parkinsonian motor symptoms including rigidity, bradykinesia, and tremor; the drug should be restarted promptly and, when discontinuation is planned in future, tapered gradually over weeks rather than stopped suddenly.
D) The postoperative deterioration is caused by the interaction between general anesthesia and amantadine ER withdrawal; the correct management is to administer intravenous amantadine, which is bioequivalent to the oral extended-release formulation, until the patient can swallow medications reliably.
E) Abrupt discontinuation of amantadine ER is the correct perioperative practice because the drug's NMDA antagonism can potentiate anesthetic agents and prolong emergence from anesthesia; the postoperative motor deterioration is an acceptable trade-off for reduced anesthetic risk.

ANSWER: C

Rationale:

Abrupt discontinuation of amantadine ER after prolonged use can precipitate significant rebound worsening of parkinsonian motor symptoms. The mechanism is not fully characterized but reflects loss of the drug's combined NMDA antagonist and dopaminergic contributions to motor function, which the basal ganglia circuit had adapted to over the course of treatment. In a hospitalized patient, abrupt loss of motor function can be particularly consequential — worsened rigidity, bradykinesia, and tremor impair the ability to participate in postoperative rehabilitation, increase fall risk, and in severe cases can contribute to immobility-related complications. The correct perioperative management of PD patients includes continuing antiparkinsonian medications on schedule through the perioperative period, including on the morning of surgery, and restarting them as soon as possible postoperatively. When discontinuation of amantadine ER is clinically necessary, it should be tapered gradually over weeks rather than stopped abruptly. Option C correctly identifies the rebound worsening mechanism and the management principle.

Option A: Option A is incorrect; the deterioration in this case is not natural disease progression — the temporal relationship with abrupt drug discontinuation is highly specific, and amantadine ER's dopaminergic contributions mean that its withdrawal can produce clinically significant motor worsening that is distinct from the underlying disease trajectory.
Option B: Option B is incorrect; while amantadine has modest dopamine-releasing activity, the rebound is not specifically dopaminergic rebound requiring levodopa dose escalation — and increasing levodopa by 50 percent risks precipitating dyskinesia and hallucinations in a postoperative patient.
Option D: Option D is incorrect; intravenous amantadine formulations are not the same as the extended-release oral formulation and are not interchangeable; restarting oral amantadine ER when the patient can swallow is the correct approach.
Option E: Option E is incorrect; there is no established clinically significant interaction between NMDA antagonist doses of amantadine and standard anesthetic agents that would justify withholding an antiparkinsonian drug through the perioperative period.

8. A 65-year-old man with Parkinson's disease (PD) on levodopa/carbidopa has been started on istradefylline 20 mg once daily for off-time reduction. Six weeks later he reports increased involuntary movements during his on-periods. Examination confirms new choreiform dyskinesia. Which of the following best explains the mechanism of this adverse effect and the appropriate management response?

A) Istradefylline has inhibited CYP3A4, increasing levodopa plasma concentrations above the dyskinesia threshold; the correct response is to discontinue istradefylline and switch to a non-CYP3A4-interacting off-time agent.
B) Istradefylline's adenosine A2A blockade has upregulated dopamine D2 receptors on striatopallidal neurons through a compensatory mechanism, increasing the sensitivity of the indirect pathway to dopamine and producing rebound hyperkinesia.
C) Istradefylline has directly stimulated dopamine synthesis in surviving nigrostriatal terminals through a presynaptic A2A receptor mechanism, raising endogenous dopamine to dyskinesia-threshold concentrations independent of levodopa dose.
D) The dyskinesia represents a class effect of all adenosine receptor antagonists and cannot be managed pharmacologically; istradefylline must be discontinued and the patient should be referred for deep brain stimulation (DBS) evaluation.
E) Istradefylline's adenosine A2A blockade reduces indirect pathway inhibitory output, facilitating increased motor activation through the thalamocortical circuit; when this increased motor drive is added to the existing dopaminergic tone from levodopa, the net effect can exceed the dyskinesia threshold, producing involuntary movements that may be managed by reducing the levodopa dose rather than discontinuing istradefylline.

ANSWER: E

Rationale:

Dyskinesia is the most common adverse effect of istradefylline and is a direct pharmacodynamic consequence of its mechanism of action. By blocking adenosine A2A receptors on striatopallidal neurons, istradefylline reduces indirect pathway inhibitory output to the globus pallidus interna (GPi), facilitating greater thalamocortical motor activation. In a levodopa-treated patient who already has baseline dopaminergic tone that is calibrated near but below the dyskinesia threshold, the additional motor facilitation provided by A2A blockade can push the net drive above the threshold, generating involuntary movements. This is not a sign of drug toxicity or an unexpected adverse reaction — it is a predictable pharmacodynamic consequence of the drug's intended mechanism. The appropriate management response is typically to reduce the levodopa dose to rebalance the overall motor drive, rather than discontinuing istradefylline, which is providing the desired off-time reduction. Option E correctly identifies this pharmacodynamic mechanism and the management principle.

Option A: Option A is incorrect; istradefylline does not meaningfully inhibit CYP3A4 — it is a substrate of CYP3A4, not an inhibitor, and does not raise levodopa concentrations through enzyme inhibition.
Option B: Option B is incorrect; D2 receptor upregulation through compensatory mechanisms is a chronic phenomenon associated with dopamine receptor supersensitivity in the context of dopamine depletion, not a mechanism of istradefylline-induced dyskinesia.
Option C: Option C is incorrect; istradefylline does not stimulate dopamine synthesis through a presynaptic A2A receptor mechanism — its action is on postsynaptic striatopallidal neurons and does not involve endogenous dopamine production.
Option D: Option D is incorrect; istradefylline-associated dyskinesia is a manageable adverse effect that responds to levodopa dose adjustment in most patients and does not require drug discontinuation or automatic referral for DBS.

9. A 55-year-old man with tremor-dominant Parkinson's disease (PD), intact cognition, and no contraindications to anticholinergic therapy is being considered for either trihexyphenidyl or benztropine. Which of the following accurately distinguishes these two agents in a way that is clinically relevant to agent selection?

A) Trihexyphenidyl is selective for muscarinic M2 receptors on cardiac tissue and is therefore contraindicated in patients with tachyarrhythmias, whereas benztropine has predominant M1 selectivity in the striatum and is the safer choice for tremor without cardiac risk.
B) Both trihexyphenidyl and benztropine are muscarinic M1 antagonists with similar therapeutic and adverse effect profiles; trihexyphenidyl is typically dosed two to three times daily and titrated to 2 to 5 mg three times daily, while benztropine has a longer duration of action permitting once or twice daily dosing at 0.5 to 2 mg, making benztropine potentially more convenient for adherence.
C) Trihexyphenidyl penetrates the blood-brain barrier (BBB) more readily than benztropine and therefore provides superior tremor control but with proportionally greater central adverse effects; benztropine's limited CNS penetrance makes it the preferred agent when cognitive safety is the primary concern.
D) Benztropine is contraindicated in patients with PD who are also taking levodopa because of a pharmacokinetic interaction in which benztropine inhibits COMT, reducing levodopa catabolism and unpredictably elevating plasma levodopa concentrations.
E) Trihexyphenidyl is preferred over benztropine in elderly patients because its shorter duration of action allows adverse effects to clear more rapidly if the drug needs to be stopped urgently, whereas benztropine's prolonged half-life means adverse effects persist for days after discontinuation.

ANSWER: B

Rationale:

Trihexyphenidyl and benztropine are both muscarinic M1 receptor antagonists used for tremor control in PD, and their pharmacological mechanisms, therapeutic effects, and adverse effect profiles are substantially similar. The clinically relevant distinctions between them are primarily pharmacokinetic and practical rather than mechanistic. Trihexyphenidyl is typically initiated at 1 mg daily and titrated to 2 to 5 mg three times daily, requiring multiple daily doses. Benztropine has a longer duration of action that permits once or twice daily dosing at 0.5 to 2 mg, which may offer a convenience advantage for patients who struggle with multiple daily doses. Neither agent has been shown to have clinically superior tremor efficacy, and the choice between them in practice is often driven by local prescribing tradition and patient preference regarding dosing schedule. Option B correctly identifies the shared M1 mechanism and the dosing frequency distinction as the primary clinically relevant difference.

Option A: Option A is incorrect; neither trihexyphenidyl nor benztropine has meaningful M2 selectivity — M2 receptors are the dominant cardiac muscarinic subtype, and both drugs block muscarinic receptors broadly, producing similar cardiovascular effects including tachycardia, not selective cardiac toxicity.
Option C: Option C is incorrect; the claim that benztropine has substantially limited CNS penetrance compared to trihexyphenidyl is not an established pharmacological distinction — both agents penetrate the CNS and produce central adverse effects; CNS penetrance is not the basis for choosing between them.
Option D: Option D is incorrect; benztropine does not inhibit COMT and has no clinically significant pharmacokinetic interaction with levodopa through this mechanism.
Option E: Option E is incorrect; the recommendation for trihexyphenidyl in elderly patients on the basis of shorter duration of action is not a guideline-based distinction, and the clinical priority in elderly patients is avoiding anticholinergics altogether rather than selecting between them on pharmacokinetic grounds.

10. An 81-year-old woman with Parkinson's disease (PD) is referred for medication review following a two-month history of progressive confusion, word-finding difficulty, and visual hallucinations. Her current medication list includes levodopa/carbidopa, benztropine 1 mg twice daily for tremor, oxybutynin 5 mg twice daily for overactive bladder, and diphenhydramine 25 mg nightly for insomnia. Cognitive testing shows moderate impairment. Which of the following represents the most appropriate intervention?

A) Reduce benztropine to 0.5 mg twice daily while maintaining oxybutynin and diphenhydramine at current doses, since benztropine is the only specifically antiparkinson anticholinergic and the other agents are treating legitimate comorbidities that would worsen without treatment.
B) Discontinue all three anticholinergic agents simultaneously and start donepezil to treat the presumed PD dementia that is causing the cognitive decline.
C) Continue all current medications and add quetiapine for hallucination management, since PD-associated psychosis requires antipsychotic treatment and the anticholinergic burden is not sufficient to explain moderate cognitive impairment.
D) Recognize that the patient is carrying a high cumulative anticholinergic burden from three agents with overlapping muscarinic blocking activity; systematically taper and discontinue each anticholinergic agent, prioritizing those with the weakest clinical indication and substituting non-anticholinergic alternatives where possible — for example, replacing oxybutynin with mirabegron for overactive bladder and replacing diphenhydramine with melatonin or a short-acting non-anticholinergic hypnotic for insomnia.
E) Add rivastigmine immediately to counteract the central anticholinergic effects pharmacologically through cholinesterase inhibition, while maintaining all three anticholinergic agents to avoid withdrawal syndromes and symptom rebound.

ANSWER: D

Rationale:

This patient's presentation — progressive confusion, word-finding difficulty, and visual hallucinations in the context of three simultaneously prescribed anticholinergic agents — is a classic presentation of cumulative anticholinergic toxicity in a PD patient with diminished cholinergic reserve. The correct intervention is systematic deprescribing of the anticholinergic burden across the entire medication list, not targeted adjustment of the single specifically antiparkinson agent. Each of the three agents contributes muscarinic blocking activity: benztropine is the directly antiparkinson anticholinergic; oxybutynin blocks muscarinic receptors in the detrusor muscle but also in the brain; diphenhydramine is a first-generation antihistamine with potent CNS-penetrant anticholinergic activity. The combined load exceeds what a patient with PD-related cholinergic depletion can tolerate. Systematic deprescribing should prioritize agents with the weakest indication or available non-anticholinergic substitutes: mirabegron (a beta-3 agonist) for overactive bladder replaces oxybutynin without anticholinergic burden; melatonin or low-dose doxepin (at doses below the anticholinergic threshold) can replace diphenhydramine for insomnia; benztropine should be tapered last, with attention to tremor management alternatives. Option D correctly identifies the cumulative burden problem and the structured deprescribing approach with non-anticholinergic substitution.

Option A: Option A is incorrect; reducing only benztropine while maintaining the other two anticholinergic agents fails to address the cumulative burden — oxybutynin and diphenhydramine are significant contributors to CNS anticholinergic toxicity, and their clinical indications do not override the need to reduce overall burden.
Option B: Option B is incorrect; discontinuing all three agents simultaneously risks precipitating withdrawal syndromes, and starting donepezil without first removing the anticholinergic burden is premature — the cognitive impairment may be entirely drug-induced and reversible.
Option C: Option C is incorrect; quetiapine is used for PD psychosis but is not appropriate here as the first intervention — the hallucinations are most likely drug-induced rather than primary PD psychosis, and treating drug-induced psychosis with an antipsychotic while maintaining the causative agents is pharmacologically illogical.
Option E: Option E is incorrect; adding rivastigmine to counteract three anticholinergic agents pharmacologically while continuing all three is not an established or appropriate strategy — it adds another drug without removing the cause, and the cholinesterase inhibitor cannot reliably overcome the muscarinic blockade from multiple agents.

11. A 62-year-old man with Parkinson's disease (PD) is being evaluated for istradefylline to reduce off-time. During the social history, he discloses a past history of gambling disorder that was successfully treated five years ago and has been in remission. Which of the following best describes the clinical significance of this history in the context of istradefylline prescribing?

A) Istradefylline carries a warning for impulse control disorders (ICDs) — including gambling disorder, hypersexuality, and compulsive shopping; a prior history of gambling disorder is clinically relevant because it identifies a patient at elevated baseline risk for ICD recurrence, warranting careful discussion of this risk before initiating the drug and heightened monitoring during treatment.
B) The impulse control disorder warning is an absolute contraindication in any patient with a prior ICD; this patient is therefore ineligible for istradefylline regardless of the duration of his remission.
C) The prior gambling disorder is not relevant to istradefylline prescribing because ICDs reported with istradefylline are confined to dopamine agonists and occur through a mesolimbic D3 receptor mechanism that istradefylline's A2A blockade does not engage.
D) The impulse control disorder warning reflects only a theoretical class-labeling requirement and not a real clinical signal; the prior gambling history requires no special consideration beyond routine prescribing.
E) Istradefylline should be withheld until the patient completes a formal neuropsychological impulse control battery, and prescribing should only proceed if the score falls below the clinical threshold for active ICD — remission history alone is insufficient to proceed without objective testing.

ANSWER: A

Rationale:

Istradefylline's prescribing information carries a warning for impulse control disorders, including pathological gambling, hypersexuality, binge eating, and compulsive shopping. These behaviors have been reported in patients taking istradefylline and represent a recognized class of adverse effects that clinicians must discuss with patients before initiation. Istradefylline is a prescription-only medication and is classified as a Schedule V controlled substance, and the impulse control disorder warning is a genuine clinical signal rather than a labeling formality. A patient with a prior gambling disorder is at elevated baseline risk for ICD recurrence when exposed to agents that carry this warning — whether through dopaminergic agonism (the mechanism implicated with dopamine agonists) or through the indirect circuit modulation produced by A2A receptor blockade. This does not constitute a contraindication to istradefylline, but it does require a substantive informed consent discussion about ICD risk, a review of current impulse control symptoms at baseline, and more frequent monitoring during treatment. Option A correctly identifies the warning and the clinical relevance of the prior ICD history.

Option B: Option B is incorrect; the impulse control disorder warning does not prohibit prescribing to patients with a history of an ICD — it is a warning that informs clinical decision-making and prompts monitoring, not an absolute prescribing exclusion.
Option C: Option C is incorrect; ICDs with istradefylline are not confined to dopamine agonists — istradefylline's prescribing information specifically lists impulse control disorders as a recognized adverse effect, and the mechanism is distinct from but not mutually exclusive with the D3 mesolimbic pathway implicated in dopamine agonist ICDs.
Option D: Option D is incorrect; the impulse control disorder warning reflects real adverse events reported in patients taking the drug, not a theoretical class-labeling requirement — dismissing it understates its clinical significance in a patient with a relevant prior history.
Option E: Option E is incorrect; formal neuropsychological testing before every istradefylline prescription is not a required or standard prescribing step — the appropriate standard is clinical screening for current ICD symptoms, informed consent discussion of risks, and monitoring during treatment.

12. A 68-year-old woman with Parkinson's disease (PD) on amantadine extended-release (ER) 137 mg at bedtime calls her neurologist's office alarmed by a new purplish, net-like discoloration of her lower legs that appeared over the past three weeks. She has no leg pain, no edema, and her feet are warm with intact pulses. She asks whether she needs to stop the amantadine immediately. Which of the following represents the most appropriate response?

A) She should stop amantadine ER immediately and present to the emergency department for urgent vascular surgery evaluation, as the finding is consistent with peripheral arterial insufficiency caused by amantadine-induced thrombotic microangiopathy.
B) The finding is consistent with dependent edema from amantadine-induced sodium and water retention; she should reduce salt intake and elevate her legs, and amantadine ER should be continued at the current dose with addition of a loop diuretic if edema worsens.
C) The finding is livedo reticularis — a recognized, benign, and reversible adverse effect of amantadine caused by cutaneous vasospasm — that does not require drug discontinuation; she should be reassured that the discoloration is a cosmetic finding, informed that it typically resolves if amantadine is stopped, and told that continuation is appropriate unless she finds it cosmetically unacceptable or other concerning features develop.
D) The finding suggests an immune-mediated vasculitis caused by amantadine and requires immediate drug discontinuation, dermatology referral, and serological testing for antineutrophil cytoplasmic antibody (ANCA) to exclude systemic vasculitis.
E) The finding is an expected and unavoidable consequence of amantadine's dopaminergic mechanism on cutaneous blood vessels; it is irreversible even after drug discontinuation and should be documented but not acted upon unless accompanied by skin breakdown or ulceration.

ANSWER: C

Rationale:

Livedo reticularis is a well-established and distinctive adverse effect of amantadine in both its immediate-release and extended-release formulations. It presents as a mottled, purplish or reddish net-like (reticular) pattern of skin discoloration of the extremities, most commonly the lower legs, caused by cutaneous vasospasm of the small dermal vessels. The clinical appearance is characteristic and, in the context of amantadine use, is readily recognizable. Critically, it is benign — it does not indicate peripheral arterial ischemia, vasculitis, or systemic disease — and it is reversible, resolving after drug discontinuation. Patients should be informed about this adverse effect proactively at the time of prescribing so they are not alarmed if it develops. Drug discontinuation is not required unless the patient finds the cosmetic appearance unacceptable or other concerning features are present (such as skin breakdown, ulceration, or pain suggesting a different diagnosis). In this patient, warm feet, intact pulses, no edema, and no pain confirm that this is not a vascular or inflammatory emergency. Option C correctly identifies the finding, reassures appropriately, and provides the correct management guidance.

Option A: Option A is incorrect; livedo reticularis from amantadine is a benign vasospastic phenomenon with no ischemic basis — the intact pulses and warm feet in this patient exclude peripheral arterial insufficiency, and emergency vascular evaluation is not warranted.
Option B: Option B is incorrect; livedo reticularis is not edema and is not caused by sodium retention — the two findings have entirely different clinical appearances and mechanisms, and a loop diuretic is not appropriate management.
Option D: Option D is incorrect; amantadine-associated livedo reticularis is not immune-mediated vasculitis — it is a recognized vasospastic adverse effect with a known mechanism, and ANCA testing is not indicated in this clinical context.
Option E: Option E is incorrect; livedo reticularis from amantadine is reversible with drug discontinuation — characterizing it as irreversible misinforms the patient and removes an important option if she later chooses to discontinue for cosmetic reasons.

13. A 64-year-old woman with Parkinson's disease (PD) has been on levodopa/carbidopa for seven years and now has functionally significant peak-dose dyskinesia despite multiple levodopa dose adjustments. Her neurologist cites clinical trial evidence to support adding amantadine extended-release (ER). Which of the following best describes the clinical trial findings that justify this recommendation, and what the evidence shows about the drug's effect on both dyskinesia and motor function during on-periods?

A) The STRIDE-PD trial demonstrated that amantadine ER reduced time to dyskinesia onset when added early in levodopa therapy, supporting its use as a preventive agent before dyskinesia becomes established rather than as a treatment for existing dyskinesia.
B) The UPDRS motor score trials showed that amantadine ER improved bradykinesia and rigidity scores by approximately 40 percent compared to placebo, identifying it primarily as a direct antiparkinson agent with dyskinesia reduction as a secondary benefit.
C) The FIRST-STEP trial demonstrated that amantadine ER 137 mg at bedtime reduced levodopa-induced dyskinesia by approximately 50 percent and simultaneously increased daily on-time by two hours compared to immediate-release amantadine, establishing its superiority over the older formulation.
D) The clinical evidence base for amantadine ER comes from uncontrolled observational studies only; no randomized controlled trial data exist because dyskinesia severity is too variable across patients to support a placebo-controlled design.
E) The EASE LID and EASE LID 3 trials demonstrated that amantadine ER at bedtime significantly reduced Unified Dyskinesia Rating Scale (UDysRS) scores compared to placebo — roughly a 46 percent reduction from baseline versus about 16 percent with placebo — while simultaneously reducing daily off-time, without worsening total on-time, establishing that dyskinesia control can be achieved without the loss of motor benefit that levodopa dose reduction would impose.

ANSWER: E

Rationale:

The EASE LID and EASE LID 3 randomized, placebo-controlled trials are the pivotal studies that supported the 2017 FDA approval of Gocovri (amantadine ER 137 mg) for levodopa-induced dyskinesia. These trials enrolled levodopa-treated PD patients with motor fluctuations and dyskinesia and demonstrated that bedtime dosing of amantadine ER produced approximately a 46 percent reduction in UDysRS scores from baseline versus approximately 16 percent with placebo — a placebo-subtracted difference of roughly 10 UDysRS points that was statistically significant and clinically meaningful. Critically, amantadine ER also reduced daily off-time as a secondary endpoint, without worsening total on-time. This dual benefit — reducing dyskinesia while simultaneously improving the proportion of the day spent in the on state — is the key clinical argument for amantadine ER over levodopa dose reduction, which would reduce dyskinesia only at the cost of increased off-time. Option E correctly identifies the trial program, the primary endpoint finding, and the clinically important secondary finding on off-time.

Option A: Option A is incorrect; STRIDE-PD was a trial of immediate-release amantadine evaluating dyskinesia prevention in early levodopa therapy, and its results were not the basis for Gocovri's dyskinesia indication — the EASE LID trials are the pivotal evidence.
Option B: Option B is incorrect; the primary efficacy endpoint of the EASE LID trials was dyskinesia (UDysRS), not UPDRS motor subscale improvement — amantadine ER is not primarily positioned as a direct antiparkinson agent for bradykinesia and rigidity; the 40 percent figure is fabricated.
Option C: Option C is incorrect; the FIRST-STEP trial does not exist as described — this option fabricates both a trial name and outcome data.
Option D: Option D is incorrect; the EASE LID and EASE LID 3 trials were randomized, double-blind, placebo-controlled studies — the evidence base is not limited to observational data.

14. A 58-year-old man with Parkinson's disease (PD) who smokes one pack of cigarettes daily is started on istradefylline 20 mg once daily for off-time reduction. At his six-week follow-up he reports minimal improvement in off-time. His neurologist considers uptitrating to 40 mg. Which of the following best explains the pharmacokinetic basis for why this patient is likely to require the higher dose, and whether uptitration is appropriate?

A) Tobacco smoking induces monoamine oxidase B (MAO-B) activity in the liver, accelerating istradefylline's oxidative deamination; uptitration to 40 mg is appropriate to compensate for this induction, but the patient should also be switched from any MAO-B inhibitor he may be taking to avoid a drug interaction with the higher istradefylline dose.
B) Tobacco smoking is a potent inducer of CYP3A4 through polycyclic aromatic hydrocarbon activation of the aryl hydrocarbon receptor; because CYP3A4 is the enzyme smoking induces, this is the pathway responsible for the reduced istradefylline exposure in smokers, and uptitration to 40 mg compensates for accelerated CYP3A4-mediated catabolism.
C) Tobacco smoking reduces istradefylline absorption through nicotine-mediated reduction of gastrointestinal motility, decreasing bioavailability; uptitration to 40 mg is appropriate but the patient should be counseled that smoking cessation would restore normal bioavailability and allow return to the 20 mg dose.
D) Tobacco smoke contains polycyclic aromatic hydrocarbons that induce the CYP1A family of enzymes (CYP1A1 and CYP1A2) through the aryl hydrocarbon receptor pathway; because istradefylline is metabolized substantially by CYP1A1, smoking accelerates its clearance and lowers plasma concentrations, so the prescribing information specifically recommends 40 mg once daily for patients who smoke 20 or more cigarettes per day.
E) Tobacco smoking has no pharmacokinetic interaction with istradefylline; the minimal response at 20 mg reflects pharmacodynamic tolerance to A2A receptor blockade that develops over the first four to six weeks of treatment, and uptitration to 40 mg is appropriate on the basis of pharmacodynamic, not pharmacokinetic, dose-response characteristics.

ANSWER: D

Rationale:

Tobacco smoke contains polycyclic aromatic hydrocarbons (PAHs) that activate the aryl hydrocarbon receptor (AhR), and the cytochrome P450 enzymes induced through this pathway are the CYP1A family — CYP1A1 and CYP1A2 — not CYP3A4. Istradefylline is metabolized primarily by CYP1A1 and CYP3A4; because CYP1A1 is one of its principal metabolic enzymes and is induced by smoking, smokers clear istradefylline more rapidly and reach lower steady-state plasma concentrations — potentially subtherapeutic at the standard 20 mg dose. For this reason the prescribing information specifically recommends a dose of 40 mg once daily for patients who smoke 20 or more cigarettes per day (or the equivalent), and steady-state exposure in heavy smokers is roughly 38 to 54 percent lower than in matched non-smokers. Uptitration to 40 mg once daily is therefore clinically appropriate and label-supported in this patient. Option D correctly identifies the CYP1A induction mechanism through PAH-mediated AhR activation and the prescribing information recommendation for smokers.

Option A: Option A is incorrect; tobacco smoking does not meaningfully induce hepatic MAO-B — MAO-B induction is not a recognized pharmacokinetic interaction with istradefylline, and istradefylline is not metabolized by oxidative deamination through MAO-B.
Option B: Option B is incorrect; the enzymes induced by PAH-mediated AhR activation are the CYP1A family, not CYP3A4 — attributing the smoking interaction to CYP3A4 induction misidentifies the pathway, even though CYP3A4 is genuinely involved in istradefylline metabolism and is the relevant enzyme for the separate rifampin and carbamazepine inducer interactions.
Option C: Option C is incorrect; istradefylline's reduced exposure in smokers is due to hepatic enzyme induction, not reduced gastrointestinal absorption from nicotine-mediated motility changes — the interaction is a metabolic, not absorptive, mechanism.
Option E: Option E is incorrect; the smoking-istradefylline interaction is pharmacokinetic and well-characterized — it is not a pharmacodynamic tolerance phenomenon, and the prescribing information directly addresses smoking as a factor requiring dose adjustment.

15. A 75-year-old man with advanced Parkinson's disease (PD) has moderate cognitive impairment and functionally significant levodopa-induced dyskinesia. He is on levodopa/carbidopa, a dopamine agonist, and a MAO-B inhibitor. His neurologist and family are discussing options for adjunct pharmacotherapy targeting the dyskinesia. Which of the following represents the most appropriate pharmacological strategy, and what monitoring is required?

A) Trihexyphenidyl should be added at 1 mg daily and titrated slowly, since the dopaminergic burden from the agonist and MAO-B inhibitor already provides anti-dyskinetic benefit and anticholinergic augmentation at low doses is safe in moderately impaired patients if titration is gradual.
B) Istradefylline 20 mg once daily should be added as the preferred agent because its A2A receptor mechanism specifically targets dyskinesia through indirect pathway rebalancing and carries no cognitive adverse effect risk compared to amantadine ER.
C) No pharmacological adjunct is appropriate in a cognitively impaired PD patient with dyskinesia; the only safe options are levodopa dose reduction or referral for deep brain stimulation (DBS) evaluation, as all adjunct agents are contraindicated by the combination of cognitive impairment and advanced disease.
D) Amantadine extended-release (ER) is the appropriate agent because it carries the specific FDA indication for levodopa-induced dyskinesia and is not contraindicated by cognitive impairment; however, it can itself cause hallucinations and worsen cognition, so initiation requires baseline cognitive and neuropsychiatric assessment, a low starting dose of 68.5 mg at bedtime for the first week, and close monitoring for neuropsychiatric adverse effects before uptitrating to 137 mg.
E) The dopamine agonist should be discontinued first and amantadine ER deferred until the effect of agonist removal on dyskinesia severity is assessed over four to six weeks, since dopamine agonist discontinuation alone resolves dyskinesia in the majority of advanced PD patients without requiring additional adjunct therapy.

ANSWER: D

Rationale:

This patient's clinical profile requires careful application of the contraindication and prescribing principles established for each agent in this module. Anticholinergics are definitively ruled out: cognitive impairment of any degree is a contraindication to their use in PD, and adding central muscarinic blockade to a patient with moderate cognitive impairment would predictably worsen cognition and risk precipitating delirium. Istradefylline addresses off-time, not dyskinesia — it is the wrong agent for the primary clinical problem. Amantadine ER holds the specific FDA indication for levodopa-induced dyskinesia and is not contraindicated by cognitive impairment as a class. However, amantadine ER can produce neuropsychiatric adverse effects including hallucinations and cognitive worsening, particularly in patients with pre-existing cognitive vulnerability. The appropriate prescribing approach therefore includes: baseline neuropsychiatric and cognitive assessment to document current status; initiating at the lower 68.5 mg starting dose for the first week as specified in the approved titration protocol; and close monitoring before uptitrating to the target 137 mg dose. This careful approach allows the drug's dyskinesia benefit to be accessed while managing the risk of neuropsychiatric adverse effects in a vulnerable patient. Option D correctly identifies amantadine ER as the appropriate agent and specifies the monitoring and titration approach.

Option A: Option A is incorrect; cognitive impairment is an absolute contraindication to anticholinergics in PD — low-dose titration does not make them safe in a cognitively impaired patient.
Option B: Option B is incorrect; istradefylline's indication is off-episode reduction, not dyskinesia management — its mechanism of indirect pathway disinhibition may actually worsen dyskinesia rather than reduce it, and it is not the correct agent for this clinical problem.
Option C: Option C is incorrect; amantadine ER is not contraindicated in cognitively impaired PD patients — it requires careful use with monitoring, but ruling out all pharmacological adjuncts and limiting options to levodopa reduction or DBS referral is an overly restrictive and incorrect conclusion.
Option E: Option E is incorrect; dopamine agonist discontinuation does not reliably resolve established levodopa-induced dyskinesia in the majority of advanced PD patients — dyskinesia is primarily driven by levodopa exposure and the sensitized striatal response to dopamine fluctuations, and agonist removal alone rarely eliminates it once established.

16. A 77-year-old man with Parkinson's disease (PD) is brought to the emergency department by his family after they found him confused and agitated at home. He takes trihexyphenidyl 4 mg three times daily, levodopa/carbidopa, and his daughter recently added her own diphenhydramine 50 mg tablets to his nightly routine "to help him sleep." On examination: temperature 38.9°C, heart rate 118 bpm, blood pressure 158/94 mmHg, dry flushed skin, markedly dilated pupils bilaterally, absent bowel sounds, and a distended bladder on palpation. He is disoriented and picking at the air. Which of the following best identifies this syndrome and its mechanistic basis?

A) This presentation represents a complete anticholinergic toxidrome resulting from the additive muscarinic blockade of trihexyphenidyl and diphenhydramine exceeding the patient's cholinergic reserve: central muscarinic blockade produces delirium and hallucinations; peripheral muscarinic blockade produces tachycardia (cardiac M2), hyperthermia (sweat gland anhidrosis), mydriasis (iris sphincter), ileus (gastrointestinal smooth muscle), and urinary retention (detrusor) — management requires discontinuing both anticholinergic agents and supportive care, with physostigmine considered for severe central toxicity.
B) This presentation is consistent with serotonin syndrome precipitated by a pharmacokinetic interaction between diphenhydramine and levodopa in which diphenhydramine inhibits aromatic amino acid decarboxylase, shunting levodopa metabolism toward serotonin; treatment requires cyproheptadine and immediate levodopa dose reduction.
C) This presentation represents neuroleptic malignant syndrome (NMS) triggered by the combined dopaminergic burden of levodopa and trihexyphenidyl; hyperthermia and rigidity are the defining features, and treatment requires immediate dantrolene infusion and dopaminergic withdrawal.
D) This presentation is consistent with levodopa toxicity from supratherapeutic plasma concentrations caused by diphenhydramine-mediated inhibition of hepatic CYP2D6, which metabolizes levodopa; treatment requires levodopa dose reduction and supportive care.
E) This presentation represents a hypertensive crisis triggered by the sympathomimetic interaction between trihexyphenidyl's alpha-adrenergic agonist activity and diphenhydramine's norepinephrine reuptake inhibition; treatment requires intravenous labetalol and discontinuation of both agents.

ANSWER: A

Rationale:

This patient presents with the complete anticholinergic toxidrome — a constellation of signs and symptoms that arise from global muscarinic receptor blockade across both peripheral and central tissues. The mnemonic "hot as a hare, dry as a bone, red as a beet, blind as a bat, mad as a hatter, full as a flask" describes this syndrome precisely. Each finding maps directly to muscarinic receptor blockade at a specific site: hyperthermia from anhidrosis (sweat glands require muscarinic stimulation to secrete); tachycardia from cardiac M2 blockade (normally vagally restrained); flushed dry skin from cutaneous vasodilation and anhidrosis; mydriasis from iris sphincter paralysis; ileus from gastrointestinal smooth muscle blockade; urinary retention with bladder distension from detrusor blockade; and delirium with hallucinations from central cortical and hippocampal muscarinic blockade. In this patient, the toxidrome was precipitated by the additive anticholinergic burden of his prescribed trihexyphenidyl 4 mg three times daily combined with diphenhydramine 50 mg nightly — each individually within a dose range that might be tolerated, but together exceeding his cholinergic reserve. Management requires discontinuing both anticholinergic agents and providing supportive care; physostigmine, a reversible acetylcholinesterase inhibitor that crosses the blood-brain barrier, can be considered for severe central anticholinergic toxicity. Option A correctly identifies the syndrome, maps its findings to specific muscarinic receptor sites, and describes appropriate management.

Option B: Option B is incorrect; serotonin syndrome presents with a triad of neuromuscular findings (clonus, hyperreflexia, tremor), autonomic instability, and altered mental status — the specific constellation of mydriasis, anhidrosis, ileus, and urinary retention with absent bowel sounds points specifically to anticholinergic toxicity, not serotonin excess; diphenhydramine does not inhibit aromatic amino acid decarboxylase.
Option C: Option C is incorrect; neuroleptic malignant syndrome requires exposure to dopamine-blocking agents and presents with severe rigidity (lead-pipe), not with the ileus and mydriasis of anticholinergic toxicity; trihexyphenidyl and levodopa are not dopamine antagonists.
Option D: Option D is incorrect; levodopa is not metabolized by CYP2D6 and does not produce a toxidrome resembling anticholinergic poisoning; elevated levodopa would cause dyskinesia and nausea, not this specific syndrome.
Option E: Option E is incorrect; trihexyphenidyl does not have alpha-adrenergic agonist activity, and diphenhydramine's weak norepinephrine reuptake inhibition does not produce hypertensive crisis through this mechanism — the hypertension in this case is a consequence of the anticholinergic state, not a primary sympathomimetic effect.